Cliff Asness's SYRE Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 17,820 shares of Spyre Therapeutics, Inc. (SYRE) worth $583,783, representing 0.00% of the portfolio. First purchased in 2024-Q3, this short-term holding has been held for 5 quarters.
Based on 13F filings, Cliff Asness has maintained this position in SYRE for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 17,973 shares. Largest reduction occurred in Q4 2024, reducing 35,003 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Spyre Therapeutics (SYRE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Spyre Therapeutics (SYRE) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +773 | Add 4.53% | 17,820 | $32.76 |
| Q3 2025 | -926 | Reduce 5.15% | 17,047 | $16.76 |
| Q2 2025 | +17,973 | New Buy | 17,973 | $14.97 |
| Q4 2024 | -35,003 | Sold Out | 0 | $0.00 |
| Q3 2024 | +35,003 | New Buy | 35,003 | $29.41 |
Cliff Asness's Spyre Therapeutics Investment FAQs
Cliff Asness first purchased Spyre Therapeutics, Inc. (SYRE) in Q3 2024, acquiring 35,003 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Spyre Therapeutics, Inc. (SYRE) for 5 quarters since Q3 2024.
Cliff Asness's largest addition to Spyre Therapeutics, Inc. (SYRE) was in Q3 2024, adding 35,003 shares worth $1.03 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 17,820 shares of Spyre Therapeutics, Inc. (SYRE), valued at approximately $583,783.
As of the Q4 2025 filing, Spyre Therapeutics, Inc. (SYRE) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Spyre Therapeutics, Inc. (SYRE) was 35,003 shares, as reported at the end of Q3 2024.